



## ANNOUNCING A NEW INTERNATIONAL SOCIETY DEDICATED TO ADVANCING THE PRACTICE OF ENDOMICROSCOPY

Paris, France and Cambridge, MA, USA, October 4, 2016 - Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, is pleased by the announcement of the creation of the **International Society for Endomicroscopy (IS4E)**.

The Society was developed from the growing need of healthcare professionals and researchers worldwide to connect and share knowledge in this ever-expanding domain. The society will serve to advance education, research and collaboration among a multi-disciplinary group of professionals. The first activities of the Society will soon to be announced.

Dr David Carr-Locke, Chief, Division of Digestive Diseases, Mount Sinai Beth Israel Medical Center, New York, first President of the IS4E declared “Endomicroscopy is either already or soon-to-be common practice in multiple specialties within gastroenterology, pulmonology, urology, surgery and research in the field of real-time digital in-vivo and ex-vivo microscopy. The creation of this professional community became a necessary step for cross-communication and we can already see membership growing to include experts, daily-users and future practitioners.”

Sacha Loiseau, Ph.D., Founder and Chief Executive Officer of Mauna Kea Technologies, said, “There is growing momentum in the adoption of endomicroscopy driven by new clinical data, medical society support, and advances in technology. The creation of an international society is a clear tribute to the importance taken by endomicroscopy in medicine and surgery and its relevance for a growing number of applications. The IS4E will play an important role in bringing together a diverse group of experts to advance the field of endomicroscopy, particularly as it continues to expand into new applications. We congratulate the founding members of the IS4E and look forward to close collaboration in the near future.”

The IS4E is an independent organization that welcomes industry support. Mauna Kea Technologies is providing the IS4E with a grant to support the formation and initial activity of the society. A first multidisciplinary meeting is planned on October 17<sup>th</sup> in Vienna, around the United European Gastroenterology Week.

### **About Mauna Kea Technologies**

Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer thanks to real time in vivo microscopic visualization. The Company's flagship product, Cellvizio, has received clearance to sell a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico. For more information on Mauna Kea Technologies, visit [www.maunakeatech.com](http://www.maunakeatech.com).

### **Disclaimer**

*This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities. Such forward looking statements are based on assumptions that Mauna Kea Technologies considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward- looking statements are subject to numerous risks and uncertainties including the risks set forth in the registration document of Mauna Kea Technologies registered by the French Financial Markets Authority (Autorité des marchés financiers (AMF)) on June 13, 2016 under number R.16-054 and available on the Company's website ([www.maunakeatech.com](http://www.maunakeatech.com)), and to the development of economic situation, financial markets, and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by Mauna Kea Technologies that differ significantly from the results, financial conditions, performances or achievements expressed in such forward-*



looking statements. This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for, Mauna Kea Technologies shares in any country.

**Mauna Kea Technologies**

Benoit Jacheet

CFO

[investors@maunakeatech.com](mailto:investors@maunakeatech.com)

**United States**

Zack Kubow / Lee Roth

The Ruth Group

646-536-7020 / 7012

[zkubow@theruthgroup.com](mailto:zkubow@theruthgroup.com) /

[lroth@theruthgroup.com](mailto:lroth@theruthgroup.com)

**U.S. Media**

Christopher Hippolyte

The Ruth Group

646-536-7023

[chippolyte@theruthgroup.com](mailto:chippolyte@theruthgroup.com)

**France and Europe**

NewCap - Investor Relations

Florent Alba

+33 (0)1 44 71 94 94

[maunakea@newcap.fr](mailto:maunakea@newcap.fr)